LDL-C Lowering
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼


Repatha® for LDL-C lowering

Repatha® delivers up to 75% additional LDL-C reduction when added to all types/doses of statin and ezetimibe.*2-5

LDL-C reduction with Repatha® by treatment and background therapy2-5

*In patients with hypercholesterolaemia/mixed dyslipidaemia, HeFH, and ASCVD on moderate- to high-intensity statins.
87% of patients were on high-intensity statins and 62% were on ezetimibe.
In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
§25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; ASCVD = Atherosclerotic cardiovascular disease; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; HeFH = Heterozygous familial hypercholesterolaemia; LDL-C = Low-density lipoprotein cholesterol; LS = Least squares; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
  2. Robinson JG, et al. JAMA. 2014;311:1870-82.
  3. Raal FJ, et al. Lancet. 2015;385:331-40.
  4. Nicholls SJ, et al. JAMA. 2016;316:2373-84.
  5. Sabatine MS, et al. N Engl J Med. 2017;376:1713-22.
  6. Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD